Enovis Corporation (NYSE: ENOV) is identified as one of the best cheap stocks poised to skyrocket. BTIG initiated coverage with a Buy rating and $41 price target on January 6, highlighting the company’s orthopedic care offerings from prevention to post-surgical recovery.

UBS recently lowered Enovis Corporation’s price target to $50 from $57, while maintaining a Buy rating. Sales projections for 2025-2027 anticipate accelerated growth with new product launches in extremities, hips, and knees, driving cash flow generation and enhancing margins.

Enovis Corporation (NYSE: ENOV) is a global medical technology company focused on musculoskeletal health solutions. The company’s innovative orthopedic devices, surgical implants, and related technologies aim to improve patient outcomes in areas like reconstruction, rehabilitation, and pain management.

While Enovis shows investment potential, other AI stocks may offer greater upside with lower risk. For insights on an undervalued AI stock poised to benefit from tariffs and onshoring trends, explore our free report on the best short-term AI stock.

For more investment insights, check out the Top 10 Materials Stocks to Buy According to Analysts, and the 10 Best Organic Food and Farming Stocks to Buy Now on Insider Monkey’s website.

Read more at Yahoo Finance: Orthopedic Innovation and Growth Potential Drive Analyst Confidence